Completed PHASE4 INTERVENTIONAL NCT00044460

Efficacy and Safety In Poorly Controlled Type 2 Diabetics

A 24-week Randomized, Double-Blind, Parallel-Group, Multicenter Study to Demonstrate the Efficacy and Safety of Two Different Rosiglitazone Dosing Regimens, 4mg OD and 8mg OD, in Poorly-Controlled Drug Naive Patients With Type 2 Diabetes Mellitus

Sponsor: GlaxoSmithKline

Conditions Diabetes Mellitus, Type 2

Interventions rosiglitazone

Updated 7 times since 2017 Last updated: Oct 5, 2017 Started: May 31, 2002 Primary completion: Apr 10, 2003 Completion: Apr 10, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Diabetes Mellitus, Type 2 and is currently completed. GlaxoSmithKline leads this study, which shows 7 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE4
Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Oct 2017 — Jun 2018 [monthly]

Completed PHASE4

Status: Active Not Recruiting → Completed
Jan 2017 — Oct 2017 [monthly]

Active Not Recruiting PHASE4

First recorded

May 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.